Inozyme Pharma, Inc.
INZY
$4.00
$0.010.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33.61% | -15.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.09% | 9.34% | |||
| Operating Income | 5.09% | -9.34% | |||
| Income Before Tax | -3.56% | -10.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.56% | -10.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.56% | -10.19% | |||
| EBIT | 5.09% | -9.34% | |||
| EBITDA | 5.12% | -9.48% | |||
| EPS Basic | -3.51% | -8.52% | |||
| Normalized Basic EPS | 3.49% | -8.53% | |||
| EPS Diluted | -3.51% | -8.52% | |||
| Normalized Diluted EPS | 3.49% | -8.53% | |||
| Average Basic Shares Outstanding | 0.05% | 1.53% | |||
| Average Diluted Shares Outstanding | 0.05% | 1.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||